No abstract available.
Quinolones* ; Vibrio vulnificus* ; Vibrio*

No abstract available.
Abscess* ; Bacteria, Aerobic* ; Quinolones* ; Virulence*

No Abstract Available.
Anti-Infective Agents* ; Enterohemorrhagic Escherichia coli* ; Quinolones* ; Shiga Toxins*

Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological profile, partial agonism with high affinity at dopamine D2-receptor, may have contributed to the development of these symptoms.
Antipsychotic Agents ; Dopamine ; Felodipine ; Female ; Humans ; Piperazines ; Quinolones ; Schizophrenia ; Aripiprazole

BACKGROUND: Moxifloxacin is an 8-methoxyquinolone compound which has been shown to have the best activity of the quinolones against M. tuberculosis but there is no literature showing the rate of cross-resistance between moxifloxacin and the other quinolones such as ofloxacin. Therefore, we tested the activity of moxifloxacin against ofloxacin resistant M. tuberculosis by a study of cross-resistance. METHODS: We tested MIC's of moxifloxacin and ofloxacin by proportion method against 34 M. tuberculosis isolates showing resistance against ofloxacin at 2.5microgram/ml concentration and 13 ofloxacin susceptible isolates from specimens submitted to clinical laboratory of National Masan Hospital from March 2003 to March 2004. RESULTS: For ofloxacin susceptible isolates, MIC(50) and MIC(90) of ofloxacin were all 1.25 microgram/ml, and MIC(50) and MIC(90) of moxifloxacin were 0.31 microgram/ml and 0.63microgram/ml respectively. For ofloxacin resistant isolates, MIC(50) of ofloxacin was over 10microgram/ml and MIC(50) of moxifloxacin was 5microgram/ml,MIC(90) of ofloxacin and moxifloxacin were all over 10microgram/ml. The rate of cross-resistance between the two was 67.6%(23/34) at 2.5microgram/ml concentration. CONCLUSIONS: Moxifloxacin showed activity against 82.4%(28/34) of ofloxacin resistant M. tuberculosis at 10microgram/ml, but more studies are needed so that moxifloxacin will be used for patient with multi-drug resistant tuberculosis including ofloxacin resistance.
Humans ; Mycobacterium tuberculosis* ; Mycobacterium* ; Ofloxacin* ; Quinolones ; Tuberculosis ; Tuberculosis, Multidrug-Resistant

OBJECTIVE: We examined the effect of long-term aripiprazole therapy on social functioning in Korean patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. METHODS: In this 52-week open-label, multicenter, single-arm study, 300 Korean patients with schizophrenia were treated with aripiprazole 10-30 mg/day after administration of 15 mg/day during the first 2 weeks. The primary efficacy measure was the Korean-Social Functioning Scale (SFS-K), and the secondary efficacy measures were the Emotion Assessment, and the Positive and Negative Syndrome Scale (PANSS) score and the Clinical Global Impression - Severity of Illness (CGI-S) to investigate for correlation between social functioning and clinical symptoms. RESULTS: At week 52, there were significant improvements in all the areas of the SFS-K. There was generally no difference in the change of social functioning between patients in the first episode and patients having previous episodes. Significant improvements were also observed in negative emotion and emotional control. Statistically significant correlation between the SFS-K and the PANSS score was observed at week 52. CONCLUSION: The present study showed that long-term treatment with aripiprazole contributed to significant improvement in social functioning in patients with schizophrenia in the long-term treatment. This improvement of social functioning was modestly associated with clinical improvement of symptoms. The results suggest that long-term aripiprazole therapy could be effective not only in treating clinical symptoms, but also in improving social functioning in patients with schizophrenia-spectrum disorder.
Humans ; Piperazines ; Prospective Studies ; Psychotic Disorders ; Quinolones ; Schizophrenia ; Aripiprazole

OBJECTIVE: This study aimed to assess the efficacy of aripiprazole for the management of cognitive impairments and hyperprolactinemia in patients with schizophrenia on a stable dose of risperidone. METHODS: Thirty-five subjects stabilized on risperidone (3-6 mg/day) for a minimum of 3 months were enrolled in a double-blind, placebo-controlled phase for 12 weeks and an open-label phase for another 12 weeks. Subjects were randomly assigned to receive 10 mg/day aripiprazole (n=17) or placebo (n=18). Over the following 12 weeks, the the aripiprazole group received a flexible dose of aripiprazole while tapering risperidone. At baseline, week 12, and week 24, subjects were evaluated using the Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Syndrome Rating Scale (ESRS), and standardized neuropsychological assessments. Serum prolactin levels were checked at baseline, week 1, week 2, and week 24. RESULTS: The mean change in total PANSS and cognitive function test scores between baseline and endpoint were similar in the aripiprazole and placebo groups. Scores on the ESRS and negative subscale of PANSS differed significantly between groups in both phases of the study (p<0.05), indicating a positive effect of aripiprazole. Compared with placebo, aripiprazole significantly reduced mean baseline serum prolactin levels within 1 week (p=0.015). CONCLUSION: Adjunctive treatment with and switching to aripiprazole were not associated with improved cognitive function in patients with schizophrenia receiving risperidone; however, aripiprazole treatment decreased negative symptoms and risperidone-induced motor side effects and lowered serum prolactin levels.
Cognition ; Humans ; Hyperprolactinemia ; Piperazines ; Prolactin ; Quinolones ; Risperidone ; Schizophrenia ; Aripiprazole

OBJECTIVES: To compare the efficacy and the safety of aripiprazole and haloperidol in the treatment of patients with delirium. METHODS: 26 patients with delirium were randomized to receive either aripiprazole or haloperidol and finally 20 patients were analyzed. We collected demographic and clinical data. The Korean Version of Delirium Rating Scale-revised-98 (K-DRS-98) and Korean Version of Drug Induced Extrapyramidal Symptom Scale (DIEPSS-K) were assessed. Blood samples were collected to analyze serum sodium ion concentration, plasma cortisol and prolactin level and pulse oximetry was used for measuring oxygen saturation. RESULTS: K-DRS-98 severity scores decreased in both groups significantly over the study period, but no statistically significant difference was observed between the two groups. No significant extrapyramidal syndromes were noted in both groups, but the use of haloperidol was associated with increased plasma prolactin level (From 24.0+/-28.1 ng/mL to 32.0+/-20.0 ng/mL, p=0.005). CONCLUSION: Aripiprazole is as effective as haloperidol in the treatment of delirium and aripiprazole may be safer than haloperidol in that haloperidol is associated with increased plasma prolactin level.
Delirium ; Haloperidol ; Humans ; Hydrocortisone ; Hyperprolactinemia ; Oximetry ; Oxygen ; Piperazines ; Plasma ; Prolactin ; Quinolones ; Sodium ; Aripiprazole

From the prudent use of quinolone in clinical practice, quinolone-resistant E. coli strains are being isolated with increasing frequency in the community as well as in the hospital. To analyze the risk factors, clinical features and prognosis of QREC, we reviewed the microbiologic records of E. coli bacteremia patients, estimated the quinolone consumption and performed the PFGE to compare genetic diversity. From 1994 to 1998, 40 episodes of QREC bacteremia were observed, 15 cases (37.5%) were hospital acquired. Overall, there is significant correlation between the increased incidence of QREC bacteremia and the upward trend in quinolone use in the hospital as out-and in-patients medication (P=0.003, r=0.98). When we compare the 40 case patients with 80 simultaneous control patients who had quinolone-susceptible E. coli bacteremia, the case patients more frequently had chronic underlying illness, prior use of quinolones and other antibiotics. Quinolone resistance was not significantly associated with higher mortality. A logistic regression analysis identified prior quinolone (P=0.001) use and prior use of other antibiotics (P=0.04) as the only independent risk factors for QREC bacteremia. 10-or 8-different PFGE patterns were observed in QREC isolates from community and hospital. They revealed little evidence of clonal spread, and may have emerged in direct response to the selective pressure exerted by antibiotic use.
Anti-Bacterial Agents ; Bacteremia* ; Genetic Variation ; Humans ; Incidence ; Logistic Models ; Mortality ; Prognosis ; Quinolones ; Risk Factors

There are many comorbid disorders associated with autism spectrum disorders in child and adolescent population. Although obsessive compulsive disorder and autism spectrum disorders (ASD) comorbidity has common in clinical practice, there are few reports about psychopharmacological treatment for obsessive compulsive symptoms in children with ASD in the literacy. We report a successful treatment case with aripiprazole in Asperger's Disorder with obsessive compulsive symptoms. The Yale Brown Obsessive Compulsive Scale was performed to assess symptom variety. This case report supports the effectiveness of aripiprazole in treatment of obsessive compulsive symptoms in Asperger's Disorder or ASDs. Aripiprazole may be beneficial to obsessive compulsive disorder comorbid autism spectrum disorders in child and adolescent age group.
Adolescent ; Asperger Syndrome ; Child ; Autism Spectrum Disorder ; Comorbidity ; Humans ; Obsessive-Compulsive Disorder ; Piperazines ; Quinolones ; Aripiprazole